CTRI/2022/02/040351尚未招募3 期
RanolazIne for heart failure with preServed Ejection fraction (HFpEF): A randomized double-blind placebo controlled trial [RISE - HFpEF study] - RISE - HFpEF study
Indian Council of Medical Research ICMR0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •(All should be satisfied)
- •1. Patients have diagnosis of symptomatic heart failure with Left Ventricular Ejection Fraction (LVEF) > 45%.
- •2. Plasma level of NT-proBNP >300 ng/mL
- •3. NYHA class II to IV heart failure
- •4. Age ââ?°Â¥ 18 years of either sex.
排除标准
- •1. Patients already on treatment with ranolazine or have been administered with ranolazine within past 24 weeks.
- •2. Patients with Acute Coronary Syndrome, cardiac surgery within period of last 24 weeks.
- •3. Patients receiving concomitant strong CYP3A4 inhibitor (e.g. diltiazem, verapamil) or inducer (e.g., rifampicin, carbamazepine).
- •4. Patients who are taking concomitant P glycoprotein inhibitor (e.g cyclosporine).
- •5. Patients who have participated in another trial in the past 3 months.
- •6. Patients with history of cardiac arrhythmia or is currently undertaking treatment with antiarrhythmic drugs
- •7. Anaemia (Hb <8g%)
- •8. HbA1c >8 g%, (for inclusion of diabetes patients)
- •9. Pregnancy and lactating mothers
- •10. not willing to follow contraceptive measures if in reproductive age group
- •11. Cirrhosis
- •12. Age > 75 years ( to have upper cut off for age as Ranolazine related ADRs are more in elderly)
- •13. HR <60 bpm
- •14. Patients with history, signs and symptoms suggestive of pericardial constriction, cor pulmonale, implanted pacemaker, implanted LVAD, implanted cardioverter - defibrillator, significant pulmonary disease (requiring active treatment with oxygen and steroid), valvular heart disease, acute decompensated heart failure.
- •16. Patients with congenital or acquired QT interval prolongation, familial history of QT interval prolongation, QTc interval of >450 ms in males and >470 ms in Females.
- •17. Patients with history of Myocardial infarction, CABG surgeryand PCI in the previous 6 month.
- •18. Patients with history of uncontrolled hypertension (blood pressure that is inadequately treated rather than blood pressure that is resistant to treatment, as might be observed with secondary causes of hypertension such as renal artery stenosis).
- •19. Patients with history of valvular heart disease.
- •20. Patients with significant pulmonary disease, COPD.
- •21. Patients who have osteoarthritis or any other conditions which would prevent him/her from performing 6 minute walk test
- •22. Patients with renal creatinine clearance ââ?°Â¤ 30 ml/min (Cockcroft - Gault formula) or with severe hepatic impairment (Child Pugh class B or Class C).
- •23. Patients who are not willing for follow up at the participating institute for a period of 6 months.
研究者
相似试验
尚未招募
不适用
Study of Ranolazine in Heart FailureCTRI/2019/02/017766Postgraduate Institute of Medical Education and Research PGIMER Chandigarh
已完成
不适用
Canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitusHeart failure with preserved ejection fraction in type 2 diabetes mellitusJPRN-UMIN000028668ara Medical Univercity80
进行中（未招募）
1 期
Effect of Ranolazine in Heart Failure PatientsHeart failure patients with preserved ejection fraction (HFpEF)MedDRA version: 20.0 Level: HLGT Classification code 10019280 Term: Heart failures System Organ Class: 10007541 - Cardiac disordersEUCTR2011-000805-27-GBMenarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg4
进行中（未招募）
不适用
Effect of Ranolazine in Heart Failure PatientsEUCTR2011-000805-27-ESMenarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg120
进行中（未招募）
不适用
Effect of Ranolazine in Heart Failure PatientsEUCTR2011-000805-27-ITMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.120